$8.34
+0.52
(+6.65%)▲
Insights on Recursion Pharmaceuticals-a
Revenue is up for the last 2 quarters, 10.10M → 10.89M (in $), with an average increase of 7.2% per quarter
Netprofit is up for the last 2 quarters, -93.01M → -92.99M (in $), with an average increase of 0.0% per quarter
6.83%
Downside
Day's Volatility :11.0%
Upside
4.47%
45.56%
Downside
52 Weeks Volatility :72.9%
Upside
50.21%
Period | Recursion Pharmaceuticals-a | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -10.23% | -1.2% | 0.0% |
6 Months | 59.46% | 10.7% | 0.0% |
1 Year | 82.89% | 5.0% | 2.1% |
3 Years | -70.72% | 15.7% | -21.9% |
Market Capitalization | 1.9B |
Book Value | $1.98 |
Earnings Per Share (EPS) | -1.58 |
Wall Street Target Price | 13.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -919.27% |
Return On Assets TTM | -32.29% |
Return On Equity TTM | -69.12% |
Revenue TTM | 44.6M |
Revenue Per Share TTM | 0.21 |
Quarterly Revenue Growth YOY | -20.4% |
Gross Profit TTM | -164.1M |
EBITDA | -325.7M |
Diluted Eps TTM | -1.58 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.72 |
EPS Estimate Next Year | -1.86 |
EPS Estimate Current Quarter | -0.45 |
EPS Estimate Next Quarter | -0.43 |
What analysts predicted
Upside of 55.88%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.7M | - |
Net Income | -62.5M | - |
Net Profit Margin | -3.7K% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.4M | ↑ 99.47% |
Net Income | -87.9M | ↑ 40.55% |
Net Profit Margin | -2.6K% | ↑ 1079.38% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 10.0M | ↑ 193.0% |
Net Income | -178.1M | ↑ 102.63% |
Net Profit Margin | -1.8K% | ↑ 794.18% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 39.7M | ↑ 296.81% |
Net Income | -239.4M | ↑ 34.45% |
Net Profit Margin | -603.36% | ↑ 1177.38% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 44.6M | ↑ 12.33% |
Net Income | -328.1M | ↑ 37.02% |
Net Profit Margin | -735.99% | ↓ 132.63% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.1M | ↑ 70.56% |
Net Income | -58.3M | ↓ 11.03% |
Net Profit Margin | -446.77% | ↑ 409.7% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.7M | ↑ 4.77% |
Net Income | -57.5M | ↓ 1.44% |
Net Profit Margin | -420.29% | ↑ 26.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↓ 11.28% |
Net Income | -60.8M | ↑ 5.76% |
Net Profit Margin | -500.98% | ↓ 80.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.0M | ↓ 9.21% |
Net Income | -76.7M | ↑ 26.22% |
Net Profit Margin | -696.5% | ↓ 195.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.1M | ↓ 8.3% |
Net Income | -93.0M | ↑ 21.23% |
Net Profit Margin | -920.78% | ↓ 224.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.9M | ↑ 7.81% |
Net Income | -93.0M | ↓ 0.02% |
Net Profit Margin | -853.88% | ↑ 66.9% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 101.4M | - |
Total Liabilities | 225.7M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 298.6M | ↑ 194.37% |
Total Liabilities | 504.9M | ↑ 123.7% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 610.3M | ↑ 104.41% |
Total Liabilities | 67.4M | ↓ 86.65% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 701.3M | ↑ 14.9% |
Total Liabilities | 215.5M | ↑ 219.67% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 653.7M | ↓ 6.79% |
Total Liabilities | 190.3M | ↓ 11.7% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 611.5M | ↓ 9.07% |
Total Liabilities | 223.5M | ↓ 4.87% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 701.3M | ↑ 14.68% |
Total Liabilities | 215.5M | ↓ 3.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 627.4M | ↓ 10.54% |
Total Liabilities | 197.2M | ↓ 8.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 666.7M | ↑ 6.27% |
Total Liabilities | 197.7M | ↑ 0.28% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 630.8M | ↓ 5.38% |
Total Liabilities | 192.9M | ↓ 2.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 653.7M | ↑ 3.63% |
Total Liabilities | 190.3M | ↓ 1.35% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -57.0M | - |
Investing Cash Flow | -3.9M | - |
Financing Cash Flow | 120.4M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -45.4M | ↓ 20.41% |
Investing Cash Flow | -8.7M | ↑ 123.53% |
Financing Cash Flow | 246.1M | ↑ 104.41% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -158.6M | ↑ 249.38% |
Investing Cash Flow | -271.7M | ↑ 3009.2% |
Financing Cash Flow | 458.5M | ↑ 86.3% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -83.5M | ↓ 47.34% |
Investing Cash Flow | 193.2M | ↓ 171.11% |
Financing Cash Flow | 154.3M | ↓ 66.34% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -54.5M | ↓ 11.49% |
Investing Cash Flow | 53.0M | ↑ 972.55% |
Financing Cash Flow | 2.3M | ↓ 12.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -44.7M | ↓ 17.96% |
Investing Cash Flow | -8.0M | ↓ 115.06% |
Financing Cash Flow | 147.3M | ↑ 6201.07% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -73.3M | ↑ 63.84% |
Investing Cash Flow | -5.3M | ↓ 33.07% |
Financing Cash Flow | 1.9M | ↓ 98.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -67.5M | ↓ 7.98% |
Investing Cash Flow | -2.1M | ↓ 61.55% |
Financing Cash Flow | 3.8M | ↑ 97.03% |
Sell
Neutral
Buy
Recursion Pharmaceuticals-a is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Recursion Pharmaceuticals-a | -4.9% | 59.46% | 82.89% | -70.72% | -70.72% |
Moderna, Inc. | 4.46% | 54.86% | -16.05% | -40.7% | 289.24% |
Regeneron Pharmaceuticals, Inc. | -8.11% | 12.56% | 10.41% | 82.28% | 161.35% |
Novo Nordisk A/s | 1.46% | 27.13% | 53.48% | 240.62% | 425.11% |
Vertex Pharmaceuticals Incorporated | -4.06% | 4.32% | 13.52% | 80.23% | 131.69% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Recursion Pharmaceuticals-a | NA | NA | NA | -1.72 | -0.69 | -0.32 | NA | 1.98 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Recursion Pharmaceuticals-a | Buy | $1.9B | -70.72% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 289.24% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 161.35% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 425.11% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 131.69% | 28.81 | 36.68% |
Baillie Gifford & Co Limited.
ARK Investment Management LLC
Vanguard Group Inc
Mubadala Investment Company PJSC
BlackRock Inc
State Street Corporation
Recursion Pharmaceuticals-a’s price-to-earnings ratio stands at None
Read Morerecursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.
Organization | Recursion Pharmaceuticals-a |
Employees | 500 |
CEO | Dr. Christopher C. Gibson Ph.D. |
Industry | Services |
Transcat Inc
$8.34
+6.65%
Telesat Corp
$8.34
+6.65%
Playa Hotels & Resorts Nv
$8.34
+6.65%
E. W. Scripps Company, Class A Shares
$8.34
+6.65%
Telecom Argentina S.a.
$8.34
+6.65%
Madison Square Garden Entertainment Corp
$8.34
+6.65%
Entrada Therapeutics, Inc.
$8.34
+6.65%
Retail Opportunity Investments Corp.
$8.34
+6.65%
Imax Corporation
$8.34
+6.65%